Mitotic drivers--inhibitors of the Aurora B Kinase

Cancer Metastasis Rev. 2009 Jun;28(1-2):185-95. doi: 10.1007/s10555-009-9184-9.

Abstract

In this article we review the basis for current anti-mitotic, anti-cancer, therapy and the potential for Aurora B kinase inhibitors as a new differentiated class of agents--"mitotic drivers". We review the current understanding of Aurora B inhibition from basic cell biology to inhibitors currently undergoing clinical trials.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Aurora Kinase B
  • Aurora Kinases
  • Cell Cycle
  • Disease Models, Animal
  • Drug Resistance, Neoplasm
  • Humans
  • Medical Oncology / methods
  • Medical Oncology / trends
  • Microtubules / drug effects
  • Mitosis*
  • Models, Biological
  • Neoplasms / metabolism*
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Serine-Threonine Kinases / antagonists & inhibitors*
  • Spindle Apparatus / drug effects

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • AURKB protein, human
  • Aurora Kinase B
  • Aurora Kinases
  • Protein-Serine-Threonine Kinases